IART (Integra Lifesciences Holdings) ROCE % : 5.30% (As of Dec. 2024)

View and export this data going back to 1995. Start your Free Trial

What is Integra Lifesciences Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Integra Lifesciences Holdings's annualized ROCE % for the quarter that ended in Dec. 2024 was 5.30%.

Integra Lifesciences Holdings ROCE % Historical Data

The historical data trend for Integra Lifesciences Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integra Lifesciences Holdings ROCE % Chart

Integra Lifesciences Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

5.34

7.96

7.52

3.76

1.59

Integra Lifesciences Holdings Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															4.97	0.93	0.37	-0.11	5.30

Integra Lifesciences Holdings ROCE % Calculation

Integra Lifesciences Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	52.395	/	( ( (3781.988 - 306.98)	+	(4037.424 - 922.126) )	/ 2 )
	=	52.395	/	( (3475.008	+	3115.298)	/ 2 )
	=	52.395	/	3295.153
	=	1.59 %

Integra Lifesciences Holdings's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	166.1	/	( ( (4065.803 - 912.563)	+	(4037.424 - 922.126) )	/ 2 )
	=	166.1	/	( ( 3153.24	+	3115.298 )	/ 2 )
	=	166.1	/	3134.269
	=	5.30 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Integra Lifesciences Holdings (NAS:IART) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Integra Lifesciences Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Integra Lifesciences Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Integra Lifesciences Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Integra Lifesciences Holdings Corp (NAS:IART) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

IL3:Germany

Address

1100 Campus Road, Princeton, NJ, USA, 08540

Website

https://www.integralife.com

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

Executives

Eric Schwartz	officer: Corp VP, Gen Counsel & Sec	C/O ERESEARCHTECHNOLOGY, INC., 1818 MARKET STREET, SUITE 1000, PHILADELPHIA PA 19103
Michael J. Mcbreen	officer: Executive VP & President, CSS	1100 CAMPUS ROAD, PRINCETON NJ 08540
Jeffrey Mosebrook	officer: SVP, Fin & PAO	311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Stuart Essig	director, officer: President and CEO	311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Barbara B Hill	director
Davis Robert T. Jr.	officer: Corp VP, Pres. Neurosurgery	INTEGRA LIFESCIENCES CORPORATION, 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Chantal Veillon-berteloot	officer: EVP & CHRO	1100 CAMPUS ROAD, PRINCETON NJ 08540
Lea Daniels Knight	officer: EVP & CFO	1100 CAMPUS ROAD, PRINCETON NJ 08540
Witte Jan De	director, officer: President & CEO	C/O RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Harvinder Singh	officer: Exec VP & PRES, International	1100 CAMPUS ROAD, PRINCETON NJ 08540
Lisa Evoli	officer: Chief Human Resources Officer	311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond G. Murphy	director	14604 CARROLTON ROAD, ROCKVILLE MD 20853
Renee Wonlai Lo	director	1100 CAMPUS ROAD, PRINCETON NJ 08540
Glenn Coleman	officer: CVP, CHIEF FINANCIAL OFFICER	C/O DENTSLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Tru St Partnership, L.p.	10 percent owner	795 EAST LANCASTER AVE., STE. 200, VILLANOVA PA 19085